Camrelizumab combined with apatinib as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A phase 2 trial

被引：0
|
作者：
Meng, Xiangrui [1 ]
Qi, Yu [1 ]
Shan, Zhengzheng [1 ]
Yang, Yang [1 ]
Fan, Qingxia [1 ]
Wang, Feng [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16087
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial
    Yang, Bo
    Guo, Xiaofeng
    Le, Cheng
    Su, Wenzhong
    Li, Xiaoming
    Zhang, Yanfeng
    Yang, Guangyi
    Liang, Weimin
    Zheng, Zhixin
    Wu, Junpeng
    Zhang, Yaowen
    Hao, Anlin
    BIOMED RESEARCH INTERNATIONAL, 2022, 2022
  • [32] NEOADJUVANT CAMRELIZUMAB IN COMBINATION WITH ALBUMIN PACLITAXEL AND CISPLATIN FOR PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC)
    Lv, Huilai
    Tian, Yang
    Li, Zhenhua
    Huang, Chao
    Xu, Yanzhao
    Tian, Ziqiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A587 - A587
  • [33] Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
    Peng Yang
    Xiao Zhou
    Xuefeng Yang
    Yuefeng Wang
    Tao Sun
    Shiying Feng
    Xianyou Ma
    World Journal of Surgical Oncology, 19
  • [34] Neoadjuvant camrelizumab plus docetaxel and carboplatin in locally advanced esophageal squamous cell carcinoma (ESCC): A prospective study
    Wang, R.
    Zhang, G.
    Zhu, Q.
    Ma, T.
    Weng, C.
    Zhang, D.
    Zeng, H.
    Wang, T.
    Gao, F.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1113 - S1113
  • [35] Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study
    Yang, Peng
    Zhou, Xiao
    Yang, Xuefeng
    Wang, Yuefeng
    Sun, Tao
    Feng, Shiying
    Ma, Xianyou
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2021, 19 (01)
  • [36] A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
    Chen, Rui
    Liu, Qianwen
    Li, Qiaoqiao
    Zhu, Yujia
    Zhao, Lei
    Liu, Shiliang
    Chen, Baoqing
    Liu, Mengzhong
    Hu, Yonghong
    Lin, Ting
    Li, Jibin
    Chen, Jiyang
    Lv, Yingxin
    Fu, Jianhua
    Xi, Mian
    Yang, Hong
    ECLINICALMEDICINE, 2023, 62
  • [37] Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial
    Chen, Yue-Yun
    Wang, Pei-Pei
    Hu, Yang
    Yuan, Yong
    Yang, Yu-Shang
    Shi, Hua-Shan
    Hao, Qing
    Lin, Zhen
    Tian, Jiang-Fang
    Zheng, Yue
    Liu, Ting
    Lin, Pan-Pan
    Xu, Heng
    Ma, Xue-Lei
    Yang, Li
    Ding, Zhen-Yu
    BRITISH JOURNAL OF CANCER, 2024, 131 (07) : 1126 - 1136
  • [38] Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma
    Leng, Xue-Feng
    Daiko, Hiroyuki
    Han, Yong-Tao
    Mao, You-Sheng
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2020, 1482 (01) : 213 - 224
  • [39] Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
    Jun Yin
    Jingnan Yuan
    Yunjin Li
    Yong Fang
    Ruoxi Wang
    Heng Jiao
    Han Tang
    Shaoyuan Zhang
    Siyun Lin
    Feng Su
    Jianmin Gu
    Tian Jiang
    Dong Lin
    Zhiliang Huang
    Chaoxiang Du
    Kui Wu
    Lijie Tan
    Qing Zhou
    Nature Medicine, 2023, 29 : 2068 - 2078
  • [40] Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
    Yin, Jun
    Yuan, Jingnan
    Li, Yunjin
    Fang, Yong
    Wang, Ruoxi
    Jiao, Heng
    Tang, Han
    Zhang, Shaoyuan
    Lin, Siyun
    Su, Feng
    Gu, Jianmin
    Jiang, Tian
    Lin, Dong
    Huang, Zhiliang
    Du, Chaoxiang
    Wu, Kui
    Tan, Lijie
    Zhou, Qing
    NATURE MEDICINE, 2023, 29 (08) : 2068 - +
12345